Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Ironwood Pharmaceuticals Inc’s stock clocked out at $0.75, down -3.04% from its previous closing price of $0.78. In other words, the price has decreased by -$3.04 from its previous closing price. On the day, 0.54 million shares were traded. IRWD stock price reached its highest trading level at $0.813 during the session, while it also had its lowest trading level at $0.7401.
Ratios:
To gain a deeper understanding of IRWD’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.12 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 1.55. For the most recent quarter (mrq), Quick Ratio is recorded 3.34 and its Current Ratio is at 3.34.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 16 ’25 when MCCOURT Thomas A sold 13,353 shares for $0.58 per share. The transaction valued at 7,745 led to the insider holds 1,147,281 shares of the business.
Gaskins Tammi L sold 2,563 shares of IRWD for $1,487 on May 16 ’25. The Chief Commercial Officer now owns 242,596 shares after completing the transaction at $0.58 per share. On May 19 ’25, another insider, MCCOURT Thomas A, who serves as the Officer of the company, bought 14,661 shares for $0.59 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IRWD now has a Market Capitalization of 121737192 and an Enterprise Value of 606657216. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.38. Its current Enterprise Value per Revenue stands at 1.91 whereas that against EBITDA is 8.015.
Stock Price History:
The Beta on a monthly basis for IRWD is 0.33, which has changed by -0.8842593 over the last 52 weeks, in comparison to a change of 0.1116153 over the same period for the S&P500. Over the past 52 weeks, IRWD has reached a high of $7.11, while it has fallen to a 52-week low of $0.53. The 50-Day Moving Average of the stock is 7.34%, while the 200-Day Moving Average is calculated to be -68.75%.
Shares Statistics:
It appears that IRWD traded 3.12M shares on average per day over the past three months and 1705140 shares per day over the past ten days. A total of 161.81M shares are outstanding, with a floating share count of 155.76M. Insiders hold about 3.74% of the company’s shares, while institutions hold 97.53% stake in the company. Shares short for IRWD as of 1749772800 were 7651319 with a Short Ratio of 2.39, compared to 1747267200 on 8467972. Therefore, it implies a Short% of Shares Outstanding of 7651319 and a Short% of Float of 7.180000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Ironwood Pharmaceuticals Inc (IRWD) is currently under the scrutiny of 2.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $0.13, with high estimates of $0.14 and low estimates of $0.12.
Analysts are recommending an EPS of between $0.21 and $0.16 for the fiscal current year, implying an average EPS of $0.19. EPS for the following year is $0.44, with 4.0 analysts recommending between $1.12 and $0.0.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $62.02M. It ranges from a high estimate of $68.3M to a low estimate of $54M. As of the current estimate, Ironwood Pharmaceuticals Inc’s year-ago sales were $94.4MFor the next quarter, 5 analysts are estimating revenue of $77.82M. There is a high estimate of $83.4M for the next quarter, whereas the lowest estimate is $69M.
A total of 5 analysts have provided revenue estimates for IRWD’s current fiscal year. The highest revenue estimate was $274.5M, while the lowest revenue estimate was $264M, resulting in an average revenue estimate of $269.28M. In the same quarter a year ago, actual revenue was $351.41MBased on 5 analysts’ estimates, the company’s revenue will be $258.74M in the next fiscal year. The high estimate is $285.3M and the low estimate is $225M.
